行情

ONTX

ONTX

Onconova医疗
NASDAQ

实时行情|Nasdaq Last Sale

0.2920
-0.0110
-3.63%
盘前: 0.2981 +0.0061 +2.09% 09:06 04/02 EDT
开盘
0.2950
昨收
0.3030
最高
0.3077
最低
0.2900
成交量
3.17万
成交额
--
52周最高
4.450
52周最低
0.1027
市值
4,883.88万
市盈率(TTM)
-0.1049
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ONTX价格均价为1.767,最高价位2.000,最低价为1.300。

EPS

ONTX 新闻

更多
  • Edited Transcript of ONTX earnings conference call or presentation 24-Mar-20 8:30pm GMT
  • Thomson Reuters StreetEvents · 1天前
  • Allakos Data, And Other News: The Good, Bad, And Ugly Of Biopharma
  • Seeking Alpha - Article · 6天前
  • Onconova Therapeutics (ONTX) Investor Presentation - Slideshow
  • Seeking Alpha - Article · 03/25 19:12
  • Onconova Therapeutics, Inc. (ONTX) CEO Steve Fruchtman on Q4 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript · 03/25 03:09

所属板块

制药
-2.46%
制药与医学研究
-2.91%

热门股票

代码
价格
涨跌幅

ONTX 简况

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company's lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.
展开

微牛提供Onconova Therapeutics Inc(NASDAQ-ONTX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ONTX股票新闻,以帮助您做出投资决策。